Mark Elliott Boulding sold $133k of PTCT
EXEC. VP AND CLO at PTC THERAPEUTICS, INC.. 2,073 shares at an average of $64.06, traded Oct 5, 2026, filed Oct 7, 2026.
Score components
- +15RoleOfficer
- +11Trade size$133k at market
- 0Share of holdings soldSold 1.9% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001578852-26-000024, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | MOption exercise Common Stock10b5-1 | +1,638 | $39.42 | $65k | 106,910 | 5 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stock10b5-1 | -1,638 | $64.03 | $105k | 105,272 | 5 d ago |
| Oct 6, 2026 | MOption exercise Common Stock10b5-1 | +435 | $39.42 | $17k | 105,707 | 5 d ago |
| Oct 6, 2026 | SOpen-market sale Common Stock10b5-1 | -435 | $64.16 | $28k | 105,272 | 5 d ago |
| Oct 5, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,638 | $0.00 | $0 | 2,894 | 5 d ago |
| Oct 6, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -435 | $0.00 | $0 | 2,459 | 5 d ago |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 39Weak | PTC THERAPEUTICS, INC. | Emma Reeve director | $934k 15,705 shares | -103% | |
| 30Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $2.9M 47,249 shares | -39% | |
| 46Moderate | PTC THERAPEUTICS, INC. | David P Southwell director | $700k 12,000 shares | -42% | |
| 30Weak | PTC THERAPEUTICS, INC. | Eric Pauwels CHIEF BUSINESS OFFICER | $2.3M 39,850 shares | -44% | |
| 39Weak | PTC THERAPEUTICS, INC. | Allan Steven Jacobson director | $84k 1,667 shares | -9% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $137k 2,813 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.